NLRP3 Inflammasome and Mineralocorticoid Receptors Are Associated with Vascular Dysfunction in Type 2 Diabetes Mellitus

Anakinra reduces blood pressure and renal fibrosis in one kidney/DOCA/salt-induced hypertension

(2017) Yeong Hann Ling et al.   PHARMACOLOGICAL RESEARCH

NLRP3 Inflammasome Mediates Aldosterone-Induced Vascular DamageClinical Perspective

(2016) Thiago Bruder-Nascimento et al.   CIRCULATION

Inflammasome activity is essential for one kidney/deoxycorticosterone acetate/salt-induced hypertension in mice

(2015) S M Krishnan et al.   BRITISH JOURNAL OF PHARMACOLOGY

Mineralocorticoid receptor blockade prevents vascular remodelling in a rodent model of type 2 diabetes mellitus

(2015) Marcondes Alves B. Silva et al.   CLINICAL SCIENCE

A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases

(2015) Rebecca C Coll et al.   NATURE MEDICINE

Diabetes impairs the vascular effects of aldosterone mediated by G protein-coupled estrogen receptor activation

(2015) Nathanne S. Ferreira et al.   Frontiers in Pharmacology

Spironolactone treatment attenuates vascular dysfunction in type 2 diabetic mice by decreasing oxidative stress and restoring NO/GC signaling

(2015) Marcondes A. B. Silva et al.   Frontiers in Physiology

The interleukin-1 receptor antagonist anakinra improves endothelial dysfunction in streptozotocin-induced diabetic rats

(2014) Susana Vallejo et al.   Cardiovascular Diabetology

Spironolactone Decreases DOCA–Salt–Induced Organ Damage by Blocking the Activation of T Helper 17 and the Downregulation of Regulatory T Lymphocytes

(2014) Cristián A. Amador et al.   HYPERTENSION

Mizoribine Ameliorates Renal Injury and Hypertension along with the Attenuation of Renal Caspase-1 Expression in Aldosterone-Salt-Treated Rats

(2014) Toshiki Doi et al.   PLoS One

The involvement of aldosterone on vascular insulin resistance: implications in obesity and type 2 diabetes

(2014) Thiago Bruder-Nascimento et al.   Diabetology & Metabolic Syndrome

Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II

(2013) Joshua A. Beckman et al.   EUROPEAN HEART JOURNAL

Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I

(2013) Francesco Paneni et al.   EUROPEAN HEART JOURNAL

Mechanisms of Diabetic Complications

(2013) Josephine M. Forbes et al.   PHYSIOLOGICAL REVIEWS

Adipocytes Produce Aldosterone Through Calcineurin-Dependent Signaling Pathways

(2012) Ana M. Briones et al.   HYPERTENSION

Vascular Actions of Aldosterone

(2012) Marie Briet et al.   JOURNAL OF VASCULAR RESEARCH

Aldosterone stimulates nuclear factor-kappa B activity and transcription of intercellular adhesion molecule-1 and connective tissue growth factor in rat mesangial cells via serum- and glucocorticoid-inducible protein kinase-1

(2011) Yoshio Terada et al.   Clinical and Experimental Nephrology

Mitochondria: Sovereign of inflammation?

(2011) Jürg Tschopp   EUROPEAN JOURNAL OF IMMUNOLOGY

T Regulatory Lymphocytes Prevent Aldosterone-Induced Vascular Injury

(2011) Daniel A. Kasal et al.   HYPERTENSION

Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice

(2010) Michael G. Usher et al.   JOURNAL OF CLINICAL INVESTIGATION

A role for mitochondria in NLRP3 inflammasome activation

(2010) Rongbin Zhou et al.   NATURE

Deletion of Mineralocorticoid Receptors From Macrophages Protects Against Deoxycorticosterone/Salt-Induced Cardiac Fibrosis and Increased Blood Pressure

(2009) Amanda J. Rickard et al.   HYPERTENSION

Aldosterone Promotes Autoimmune Damage by Enhancing Th17-Mediated Immunity

(2009) Andrés A. Herrada et al.   JOURNAL OF IMMUNOLOGY

Spironolactone for poorly controlled hypertension in type 2 diabetes: conflicting effects on blood pressure, endothelial function, glycaemic control and hormonal profiles

(2008) K. Swaminathan et al.   DIABETOLOGIA

Aldosterone and Vascular Inflammation

(2008) Nancy J. Brown   HYPERTENSION